scholarly journals Comprehensive Analysis of mRNA Expression Profiling and Identification of Potential Diagnostic Biomarkers in Coronary Artery Disease

ACS Omega ◽  
2021 ◽  
Author(s):  
Jia-Xin Chen ◽  
Shu He ◽  
Yan-Jun Wang ◽  
Xiong-Kang Gan ◽  
Ya-Qing Zhou ◽  
...  
Gene ◽  
2011 ◽  
Vol 487 (1) ◽  
pp. 103-106 ◽  
Author(s):  
Javad Tavakkoly-Bazzaz ◽  
Parvin Amiri ◽  
Mohammad Tajmir-Riahi ◽  
Daryoosh Javidi ◽  
Maryam Khojasteh-Fard ◽  
...  

2010 ◽  
Vol 119 (8) ◽  
pp. 335-343 ◽  
Author(s):  
Chiara Taurino ◽  
William H. Miller ◽  
Martin W. McBride ◽  
John D. McClure ◽  
Raya Khanin ◽  
...  

Owing to the dynamic nature of the transcriptome, gene expression profiling is a promising tool for discovery of disease-related genes and biological pathways. In the present study, we examined gene expression in whole blood of 12 patients with CAD (coronary artery disease) and 12 healthy control subjects. Furthermore, ten patients with CAD underwent whole-blood gene expression analysis before and after the completion of a cardiac rehabilitation programme following surgical coronary revascularization. mRNA and miRNA (microRNA) were isolated for expression profiling. Gene expression analysis identified 365 differentially expressed genes in patients with CAD compared with healthy controls (175 up- and 190 down-regulated in CAD), and 645 in CAD rehabilitation patients (196 up- and 449 down-regulated post-rehabilitation). Biological pathway analysis identified a number of canonical pathways, including oxidative phosphorylation and mitochondrial function, as being significantly and consistently modulated across the groups. Analysis of miRNA expression revealed a number of differentially expressed miRNAs, including hsa-miR-140-3p (control compared with CAD, P=0.017), hsa-miR-182 (control compared with CAD, P=0.093), hsa-miR-92a and hsa-miR-92b (post- compared with pre-exercise, P<0.01). Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2×10−16). In conclusion, using whole blood as a ‘surrogate tissue’ in patients with CAD, we have identified differentially expressed miRNAs, differentially regulated genes and modulated pathways which warrant further investigation in the setting of cardiovascular function. This approach may represent a novel non-invasive strategy to unravel potentially modifiable pathways and possible therapeutic targets in cardiovascular disease.


2017 ◽  
Vol 263 ◽  
pp. e277
Author(s):  
Cecile Vindis ◽  
Julien Faccini ◽  
Jean-Bernard Ruidavets ◽  
Pierre Cordelier ◽  
Frederic Martins ◽  
...  

2017 ◽  
Vol 117 (03) ◽  
pp. 429-436 ◽  
Author(s):  
Jie Gao ◽  
Xiaojuan Ma ◽  
Ying Zhang ◽  
Ming Guo ◽  
Dazhuo Shi

SummaryThe acute cardiovascular events following thrombus formation is a primary cause of morbidity and mortality of patients with coronary artery disease (CAD). Numerous studies have shown that a prethrombotic status, which can be defined as an imbalance between the procoagulant and anticoagulant conditions, would exist for a period of time before thrombogenesis. Therefore, early diagnosis and intervention of prethrombotic status are important for reducing acute cardiovascular events. However, none of prethrombotic indicators have been identified as golden standard for diagnosis of prethrombotic status to date. MicroRNAs (miRNAs), a class of short non-coding RNAs, have been shown to be involved in pathophysiologic processes related to prethrombotic status, such as endothelial dysfunction, platelet activation, impaired fibrinolysis and elevated procoagulant factors, etc. Owing to their multiple and fine-tuning impacts on gene expression, miRNAs raise a novel understanding in the underlying mechanism of prethrombotic status. This review aims to discuss the role of miRNAs in prethrombotic status, especially the differently expressed miRNAs in CAD, which may be meaningful for developing promising diagnostic biomarkers and therapeutic strategies for CAD patients in future.


2012 ◽  
Vol 39 (9) ◽  
pp. 8595-8599 ◽  
Author(s):  
Mahsa M. Amoli ◽  
Parvin Amiri ◽  
Amin Alborzi ◽  
Bagher Larijani ◽  
Sadaf Saba ◽  
...  

2019 ◽  
Vol 28 (9) ◽  
pp. 1243-1248
Author(s):  
Paulina Jackowska ◽  
Maciej Chałubiński ◽  
Emilia Łuczakl ◽  
Katarzyna Wojdan ◽  
Paulina Gorzelak-Pabis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document